Best Practice & Research Clinical Rheumatology
Volume 21, Issue 4 , Pages 663-675 , August 2007

The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care

References 

  1. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annual Review of Immunology. 1996;14:397–440
  2. Smolen JS, Steiner G. Therapeutic strategies for rheumatoid arthritis. Nature Reviews Drug Discovery. 2003;2:473–488
  3. Mallya RK, de Beer FC, Hamilton ED, et al. Correlation of clinical parameters of disease activity in rheumatoid arthritis with serum concentrations of C-reactive protein and erythrocyte sedimentation rate. Journal of Rheumatology. 1982;9:224–228
  4. Aletaha D, Machold KP, Nell VPK, Smolen JS. The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey. Rheumatology. 2006;45:1133–1139Epub 2006 Mar 7
  5. van der Heijde DM, Van't Hof MA, van Riel PL, et al. Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Annals of Rheumatic Disease. 1992;51:177–181
  6. van Leeuwen MA, van Rijswijk MH, Sluiter WJ, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. Journal of Rheumatology. 1997 Jan;24(1):20–27
  7. Aletaha D, Nell VPK, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: Validation of a clinical activity score. Arthritis Research. 2005;7:R796–R806
  8. van Leeuwen MA, Van der Heijde DM, van Rijswijk MH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. Journal of Rheumatology. 1994 Mar;21(3):425–429
  9. Pincus T, Callahan LF, Sale WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis and Rheumatism. 1984;27:864–872
  10. Sokka T, Kautiainen H, Mottonen T, Hannonen P. Work disability in rheumatoid arthritis 10 years after the diagnosis. Journal of Rheumatology. 1999 Aug;26(8):1681–1685
  11. Pincus T, Callahan LF. Early mortality in RA predicted by poor clinical status. Bulletin on the Rheumatic Diseases. 1992;41(4):1–4
  12. Aletaha D, Smolen JS, Ward MM. Measuring function in rheumatoid arthritis: identifying reversible and irreversible components. Arthritis and Rheumatism. 2006;54:2784–2792
  13. Drossaers-Bakker KW, de Buck M, van Zeben D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis and Rheumatism. 1999;42:1854–1860
  14. Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis and Rheumatism. 2001 Sep;44(9):2009–2017
  15. Smolen JS, Han C, Bala M, et al. Evidence of Radiographic Benefit of Infliximab Plus Methotrexate in Rheumatoid Arthritis Patients Who Had No Clinical Improvement: A Detailed Subanalysis of the ATTRACT Trial. Arthritis and Rheumatism. 2005;52:1020–1030
  16. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis and Rheumatism. 2006;54:26–37
  17. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis and Rheumatism. 2004;50:1400–1411
  18. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–681
  19. Lipsky PE, Van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. New England Journal of Medicine. 2000 Nov 30;343(22):1594–1602
  20. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis and Rheumatism. 2004;50:3432–3443
  21. Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis and Rheumatism. 2006;54:2739–2806
  22. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Annals of Internal Medicine. 2006 Jun 20;144(12):865–876
  23. Goekoop-Ruiterman YP, de Vrie-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis and Rheumatism. 2005;52:3381–3390
  24. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–269
  25. Boers M, Tugwell P, Felson DT, et al. WHO and ILAR core endpoints for symptom modifying antirheumatic drugs in RA clinical trials. Journal of Rheumatology. 1994;21(Supplement 41):86–89
  26. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism. 1993;36:729–740
  27. Scott DL, Panayi GS, van Riel PLCM, et al. Disease activity in rheumatoid arthritis -preliminary report of the Consensus Study Group of the European Workshop for Rheumatology Research. Clinical and Experimental Rheumatology. 1992;10:521–525
  28. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism. 1995;38:727–735
  29. Van der Heijde DMFM, van't Hof M, van Riel PL, van de Putte LBA. Development of a Disease activity score based on judgement in clinical practice by rheumatologists. Journal of Rheumatology. 1993;20:579–581
  30. van Gestel AM, van Riel PLCM. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis and Rheumatism. 1998;41:1845–1850
  31. Pincus T, Wolfe F. An infrastructure of patient questionnaires at each rheumatology visit: improving efficiency and documenting care. (Editorial). Journal of Rheumatology. 2000;27:2727–2730
  32. Aletaha D, Smolen JS. The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases. Rheumatic Diseases Clinics of North America. 2006;32:9–44
  33. Siegel JN, Zhen B-G. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis. Argument in Favor. Arthritis and Rheumatism. 2005;52:1637–1641
  34. Boers M. Use of the American College of Rheumatology N (ACR-N) index of improvement in rheumatoid arthritis. Argument in Opposition. Arthritis and Rheumatism. 2005;52:1642–1645
  35. Aletaha D, Smolen JS. The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers. Arthritis and Rheumatism. 2006 Jan;54(1):377–378
  36. Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patients and trial profiles. Journal of Rheumatology. 1993;20:561–565
  37. van der Heijde DMFM, Van't Hof MA, van Riel PLCM, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Annals of Rheumatic Diseases. 1990;49:916–920
  38. van Gestel AM, Prevoo MLL, Van't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis and Rheumatism. 1996;39:34–40
  39. Egan BM, Lackland DT, Cutler NE. Awareness, knowledge, and attitudes of older americans about high blood pressure: implications for health care policy, education, and research. Archives of Internal Medicine. 2003 Mar 24;163(6):681–687
  40. Rachmani R, Slavacheski I, Berla M, et al. Treatment of high-risk patients with diabetes: motivation and teaching intervention: a randomized, prospective 8-year follow-up study. Journal of the American Society of Nephrology. 2005 Mar;16(Supplement 1):S22–S26
  41. Eberl G, Studnicka-Benke A, Hitzelhammer J, et al. Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology. 2000;39:148–155
  42. Smolen JS, Breedveld FC, Schiff MH, et al. A Simplified Disease Activity Index for Rheumatoid Arthritis For Use In Clinical Practice. Rheumatology. 2003;42:244–257
  43. Wolfe F, Michaud K. The clinical and research significance of the erythrocyte sedimentation rate. Journal of Rheumatology. 1994 Jul;21(7):1227–1237
  44. Wolfe F, Pincus T. The level of inflammation in rheumatoid arthritis is determined early and remains stable over the longterm course of the illness. Journal of Rheumatology. 2001 Aug;28(8):1817–1824
  45. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis and Rheumatism. 2005;52:2625–2636
  46. Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clinical and Experimental Rheumatology. 2005;23(Suppl 39):S100–S108
  47. Aletaha D, Smolen JS, Ward MM. Functional limitation in rheumatoid arthritis: how much is reversible?. Arthritis and Rheumatism. 2005;52(Supplement):
  48. Felson D. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis and Rheumatism. 2007;57:193–202
  49. Soubrier M, Zerkak D, Gossec L, et al. Which Variables Best Predict Change in Rheumatoid Arthritis Therapy in Daily Clinical Practice?. Journal of Rheumatology. Apr 15 2006;[Epub ahead of print]
  50. Lissiane K, Guedes N, Kowalski SC, et al. The new indices Sdai and Cdai in early arthritis: similar performance to the Das28 index. Arthritis and Rheumatism. 2006;54(Supplement):S206–S207
  51. Lian TY, Koh ET, RA study group TTSH, Kong KO. Clinical Disease Activity Index (CDAI) is a valid instrument for assessing disease activity amongst oriental early rheumatoid arthritis (ERA) patients. Arthritis and Rheumatism. 2006;54(Supplement):S377–S378
  52. Makinen H, Kautiainen H, Hannonen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?. Annals of Rheumatic Diseases. 2005;64:1410–1413originally published online 7 Jun 2005; doi:10.1136/ard.2005.037333
  53. van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Annals of Rheumatic Diseases. 2005;64:1582–1587
  54. Mierau M, Schoels M, Gonda G, et al. Assessing remission in clinical practice. Rheumatology. 2007;46(6):975–979
  55. Molenaar ET, Voskuyl AE, Dijkmans BA. Functional disability in relation to radiological damage and disease activity in patients with rheumatoid arthritis in remission. Journal of Rheumatology. 2002 Feb;29(2):267–270
  56. Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions?. Clinical and Experimental Rheumatology. 2006;(Supplment 43):S045–S051
  57. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis and Rheumatism. 2006 Aug 31;54(9):2817–2829
  58. Aletaha D, Smolen JS, Kvien TK. Definition of Moderate and Major Response for Disease Activity Indices in Rheumatoid Arthritis (RA). Annals of Rheumatic Diseases. 2006;65(Suppl II):692
  59. Smolen JS, van der Heijde DMFM, St. Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate without or with concomitant infliximab. Results from the ASPIRE trial. Arthritis and Rheumatism. 2006;54:702–710
  60. Smolen JS, Sokka T, Pincus T, Breedveld FC. A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures. Clinical and Experimental Rheumatology. 2003;21(Supplement 31):S209–S210

PII: S1521-6942(07)00020-4

doi: 10.1016/j.berh.2007.02.004

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 4 , Pages 663-675 , August 2007

Article Tools

* Image Usage & Resolution